PolyPid Total Liabilities
PolyPid total liabilities. Based on the latest financial reports, PolyPid (PYPD) has total liabilities worth $11.33 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PYPD asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PolyPid (2012–2025)
Total liabilities of PolyPid from 2012 to 2025. This chart illustrates how PolyPid's total liabilities have evolved over time, based on quarterly financial data.
PolyPid Competitors by Total Liabilities
The table below lists competitors of PolyPid ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IS:YATAS
|
Turkey | TL11.40 Billion |
|
BaoMinh Insurance Corp
VN:BMI
|
Vietnam | ₫4.60 Trillion |
|
Manba Finance Ltd
NSE:MANBA
|
India | Rs14.99 Billion |
|
Cufe Ltd
AU:CUF
|
Australia | AU$1.23 Million |
|
Dong Yang Pipe
KO:008970
|
Korea | ₩98.08 Billion |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
USA | $2.49 Million |
|
Asetek A/S
F:A31
|
Germany | €35.78 Million |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $7.56 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down PolyPid's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PYPD total assets.
Liquidity & Leverage Metrics
PolyPid Total Liabilities Ratios Explained
PolyPid total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PolyPid's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PolyPid (2012–2025)
The table below shows the annual total liabilities of PolyPid from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.33 Million | -35.37% |
| 2024-12-31 | $17.54 Million | +0.39% |
| 2023-12-31 | $17.47 Million | -13.28% |
| 2022-12-31 | $20.14 Million | +143.41% |
| 2021-12-31 | $8.28 Million | +169.54% |
| 2020-12-31 | $3.07 Million | +8.48% |
| 2019-12-31 | $2.83 Million | -97.06% |
| 2018-12-31 | $96.19 Million | -13.83% |
| 2017-12-31 | $111.63 Million | +109.85% |
| 2016-12-31 | $53.20 Million | +1862.23% |
| 2015-12-31 | $2.71 Million | -72.94% |
| 2013-12-31 | $10.02 Million | +64.30% |
| 2012-12-31 | $6.10 Million | -- |
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more